nutch_noindex
CANCELAR
COVID-2019 Alert

Information about the 2019 Novel Coronavirus. Read the latest >

Información sobre el coronavirus 2019 (COVID-19). Aprenda más >

/nutch_noindex

John Yost, MD

  • Clinical Associate Professor
Añadir a contactos (información)
  • No hay imagen

Ubicaciones y Horarios

Dermatology Clinic - North Campus

450 Broadway St
Pavilion B
Redwood City, CA 94063
Teléfono: (650) 723-6316
Mapa de Direcciones y Estacionamiento

Stanford Cancer Center

900 Blake Wilbur Dr
3rd Fl
Stanford, CA  94305
Mapa de Direcciones y Estacionamiento

Especialidades médicas y/o especialidades quirúrgicas

Dermatology

Trabajo y educación

Educación

University of Michigan Medical School, Ann Arbor, MI, 5/14/2010

Primeros años de residencia

Oakwood Hospital and Medical Center, Dearborn, MI, 6/30/2011

Últimos años de residencia

New York University Dermatology Residency, New York, NY, 6/30/2014

Certificado(s) de especialidad

Dermatology, American Board of Dermatology

Todo Publicaciones

Pernio-like eruption associated with COVID-19 in skin of color. JAAD case reports Daneshjou, R., Rana, J., Dickman, M., Yost, J. M., Chiou, A., Ko, J. 2020; 6 (9): 89297

View details for DOI 10.1016/j.jdcr.2020.07.009

View details for PubMedID 32835046

Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With > 50% Baseline Infection JOURNAL OF DRUGS IN DERMATOLOGY Pariser, D. M., Wendelken, M. E., Rycerz, A. M., Lowe, N., Yost, J., Lipner, S. R. 2018; 17 (2): 16872

Abstract

Women with onychomycosis may suffer more effects on their quality of life than men. There is limited female-specific data on the treatment of onychomycosis. Tavaborole is a topical treatment option for onychomycosis. This post-hoc study evaluated the nail plates of women using data from the tavaborole 5% Phase III studies at baseline and end of study for the areas of healthy nail and infected nail. Over 52 weeks (48-week treatment, 4-week follow up), women treated with tavaborole had an average 32% increase in healthy nail and 21% decrease in infected nail. Patients with baseline infection involving >50% of the nail plate had an average increase in percentage of unaffected nail surface area of 81% and a corresponding 51% decrease in infected nail. These analyses suggest that patients with the greatest toenail involvement at baseline had greater overall improvements than those who were less affected. This evaluation provides additional clinical guidance for treating women with onychomycosis using tavaborole. J Drugs Dermatol. 2018;17(2):168-172.

View details for Web of Science ID 000424534100005

View details for PubMedID 29462224

Neurogenic Rosacea: A Distinct Clinical Subtype Requiring a Modified Approach to Treatment ARCHIVES OF DERMATOLOGY Scharschmidt, T. C., Yost, J. M., Truong, S. V., Steinhoff, M., Wang, K. C., Berger, T. G. 2011; 147 (1): 123-126

View details for Web of Science ID 000286229000035

View details for PubMedID 21242409